290 related articles for article (PubMed ID: 25376267)
21. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
22. EPICO 3.0. Antifungal prophylaxis in solid organ transplant recipients.
Zaragoza R; Aguado JM; Ferrer R; Rodríguez AH; Maseda E; Llinares P; Grau S; Muñoz P; Fortún J; Bouzada M; Pozo JC; León R;
Rev Iberoam Micol; 2016; 33(4):187-195. PubMed ID: 27067875
[TBL] [Abstract][Full Text] [Related]
23. Echinocandin use in lung transplant recipients.
Al Jishi Y; Rotstein C; Kumar D; Humar A; Singer LG; Keshavjee S; Husain S
Clin Transplant; 2018 Dec; 32(12):e13437. PubMed ID: 30375050
[TBL] [Abstract][Full Text] [Related]
24. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
McCoy D; Depestel DD; Carver PL
Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
[TBL] [Abstract][Full Text] [Related]
25. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.
Kett DH; Shorr AF; Reboli AC; Reisman AL; Biswas P; Schlamm HT
Crit Care; 2011; 15(5):R253. PubMed ID: 22026929
[TBL] [Abstract][Full Text] [Related]
26. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
27. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
28. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
[TBL] [Abstract][Full Text] [Related]
29. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
[TBL] [Abstract][Full Text] [Related]
30. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
[TBL] [Abstract][Full Text] [Related]
31. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study.
Biancofiore G; Bindi ML; Baldassarri R; Romanelli AM; Catalano G; Filipponi F; Vagelli A; Mosca F
Transpl Int; 2002 Jul; 15(7):341-7. PubMed ID: 12122510
[TBL] [Abstract][Full Text] [Related]
32. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients.
Playford EG; Webster AC; Sorrell TC; Craig JC
Eur J Clin Microbiol Infect Dis; 2006 Sep; 25(9):549-61. PubMed ID: 16912905
[TBL] [Abstract][Full Text] [Related]
33. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
Wingard JR; Carter SL; Walsh TJ; Kurtzberg J; Small TN; Baden LR; Gersten ID; Mendizabal AM; Leather HL; Confer DL; Maziarz RT; Stadtmauer EA; Bolaños-Meade J; Brown J; Dipersio JF; Boeckh M; Marr KA;
Blood; 2010 Dec; 116(24):5111-8. PubMed ID: 20826719
[TBL] [Abstract][Full Text] [Related]
34. Invasive fungal infections in liver transplantation.
Liu X; Ling Z; Li L; Ruan B
Int J Infect Dis; 2011 May; 15(5):e298-304. PubMed ID: 21345708
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients.
Hadley S; Huckabee C; Pappas PG; Daly J; Rabkin J; Kauffman CA; Merion RM; Karchmer AW
Transpl Infect Dis; 2009 Feb; 11(1):40-8. PubMed ID: 19144094
[TBL] [Abstract][Full Text] [Related]
36. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study.
Pappas PG; Andes D; Schuster M; Hadley S; Rabkin J; Merion RM; Kauffman CA; Huckabee C; Cloud GA; Dismukes WE; Karchmer AW
Am J Transplant; 2006 Feb; 6(2):386-91. PubMed ID: 16426325
[TBL] [Abstract][Full Text] [Related]
37. Once weekly fluconazole for antifungal prophylaxis post-liver transplantation.
Trudeau RE; Bowman LJ; Wills AR; Crippin JS; Chapman WC; Anderson C
HPB (Oxford); 2013 Jul; 15(7):541-7. PubMed ID: 23458063
[TBL] [Abstract][Full Text] [Related]
38. The incidence of fungal infections in pancreas transplant recipients in the absence of systemic antifungal prophylaxis.
Shaikh SA; Zimmerman A; Nolan A; Cooper M; Abrams PL
Clin Transplant; 2019 Oct; 33(10):e13691. PubMed ID: 31400149
[TBL] [Abstract][Full Text] [Related]
39. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
Ziakas PD; Kourbeti IS; Mylonakis E
Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
[TBL] [Abstract][Full Text] [Related]
40. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
